Diligence memo · auto-generated · as of July 3, 2026
NanoView Biosciences, Inc.
NanoView Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
NanoView Biosciences, Inc. operates in Biotechnology, based in BOSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NanoView Biosciences, Inc. has raised $18M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.0M on 2018-09-20.
Most recent recorded round closed around 2022-02-15.
Valuation (modeled)modeled
Provath models NanoView Biosciences, Inc. at approximately $41M (range $2.7M–$154M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.93× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 66% of Biotechnology peers (4293 compared).
Modeled value ranks above 41% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.